Slide 1: Cover letter to stock exchanges: Investor Presentation Q2 results
Vimta Labs Limited Registered Office 142, IDA Phase II. Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 40 2726 4141 F : +91 402726 3657 VimiDriven by Quality. Inspired by Science. V LL\SE\0 59\ 2024-25 Date: 08.11.2024 Listing Centre Asst Vice President B S 1* Limited National Stock Exchange
Slide 2: Investor Presentation Q2 & H1 FY25
Vimta Labs Limited Investor Presentation Q2 & H1 FY25 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Contents
Contents Q2 & H1 FY25 Earnings 1 Company Overview 2 Industry Landscape 3 Our Competitive Advantage 4 Way Forward 5 3
Slide 5: Q2 & H1 FY25 Earnings
Q2 & H1 FY25 Earnings ▪ Q2 & H1 FY25 Highlights ▪ Key Metrics: Q2 & H1 FY25 ▪ Profit & Loss Statement ▪ Balance Sheet ▪ Financial Track Record ▪ Shareholding Pattern 01 4
Slide 6: Q2 & H1 FY25 Highlights
Q2 & H1 FY25 Highlights Q2 FY25 Earnings Highlights ➢ Total Income for Q2 FY25 was at Rs. 854 Mn ➢ EBITDA for Q2 FY25 was Rs. 306 Mn; EBITDA margin was at 35.8% ➢ Q2 FY25 PAT was at Rs. 170 Mn ➢ Basic EPS in Q2 FY25 was Rs. 7.7 H1 FY25 Earnings Highlights ➢ Total Income for H1 FY25 was at Rs. 1,610
Slide 7: Key Metrics: Q2 & H1 FY25
Key Metrics: Q2 & H1 FY25 Q2 FY25 SNAPSHOT* Total Income (In ₹ Mn) EBIDTA & EBIDTA Margin1 (In ₹ Mn, %) PAT & PAT Margin1 (In ₹ Mn, %) Basic EPS (In ₹) 35.2% 35.8% 18.4% 19.9% 28.8% 12.0% 200 25. 0% 250.00 175 225.00 5 20. 0% 200.00 150 175.00 125 15. 0% 150.00 100 125.00 10. 0% 100.00 75 26.4% 75.0
Slide 8: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q2 FY25 Q2 FY24 YoY (%) Q1 FY25 QoQ(%) H1 FY25 H1 FY24 YoY (%) Revenue from Operations 847 655 749 1,596 1,413 Other Income 7 20 7 14 26 Total Income 854 676 26.4% 756 13.0% 1,610 1,439 11.9% Material and Testing Costs 182 135 143 325 289 Cost of lab setup
Slide 9: Balance Sheet
Balance Sheet 31 March 2024 31 March 2023 Particulars (₹ Mn) 30 September 2024 (Unaudited) (Audited) (Audited) Assets Fixed Assets 1,698 1,564 1,570 Capital work-in-progress 748 586 123 Goodwill 56 56 56 Intangible assets 76 91 122 Other non-current assets 108 128 116 Total non-current assets 2,685
Slide 10: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 40% 19% 36% 15% 15% 20% 13% 29% 31% 28% 20% 10% 25% 18% 4% 10% 11.9% 22.4% 43.2% 1,837 2,115 2,797 3,216 3,223 1,610 330 538 817 984 908 572 214 413 482 410 309 CAGR CAGR 68 CAGR 0% 0% FY20 FY21 F
Slide 11: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th September 2024 Share Information as on 30th September 2024 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 1,203.97 % free-float 63.11% Others Promoters Free-float market cap (INR Cr) 759.80 59.8% 36.9% Total Debt (INR Mn) 116 Cash & Cash Equiv
Slide 12: Company Overview
Company Overview ▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation 02 11
Slide 13: Vimta Labs at a Glance
Vimta Labs at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics
Slide 14: Our Journey
Our Journey ` ` Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2023 400,000+ ft2 1400+ 492 M development services; Food; 3,216 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & Food; 400,000+ ft2 1000+ 580 M Clinical Resear
Slide 15: Our Offerings (1/3)
Our Offerings (1/3) Drug discovery and development support to Food & Agriculture Electronics & Environment Testing & Lifesciences Industry Services Electricals Testing Consultancy Offerings Pharma Analytical Clinical Research Preclinical Support Industry Pharmaceuticals Pharmaceuticals Pharmaceutica
Slide 16: Our Offerings (2/3)
Our Offerings (2/3) Drug discovery and development support to Food & Agriculture Electronics & Environment Testing & Lifesciences Industry Services Electricals Testing Consultancy Offerings Food Testing No. of Laboratories 6 Accreditations & Regulatory FSSAI, NABL, BIS, APEDA, EIC, Spices Board Appr
Slide 17: Our Offerings (2/3): Electronics & Electricals Testing
Our Offerings (2/3) Drug discovery and development support to Food & Agriculture Electronics & Environment Testing & Lifesciences Industry Services Electricals Testing Consultancy Offerings Electronics & Electricals Testing No. of Laboratories 1 Accreditations & Regulatory ISO 17025 accredited by NA
Slide 18: Our Offerings (3/3)
Our Offerings (3/3) Drug discovery and development support to Food & Agriculture Electronics & Environment Testing & Lifesciences Industry Services Electricals Testing Consultancy Offerings Environment Testing & Consultancy No. of Laboratories NA Accreditations & Regulatory MoEF, ISO 17025 by NABL,
Slide 19: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 9 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Hyderabad (Headquarters) Food Pharma Electronics & Electrical Environment Food Environment Ahmedabad Chennai Noida Noida Mumbai (NFL) Kolkata Bengaluru Nello
Slide 20: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Executive Chairman Managing Director Executive Director Dr. S P Vasireddi is a Scientist – Technocrat – Harita has close to 25 years of Sreenivas’s core competencies include Entrepreneur having more than 45 years of experience i
Slide 21: Key Management Team (Cont’d)
Key Management Team (Cont’d) Harriman Vungal Suresh Kumar Narahari Naidu D.R. Executive Director - Operations President Chief Financial Officer Harriman was inducted to the Board as one Suresh have more than two decades of Narahari has close to 15 years of experience of the Promoter Directors in 199
Slide 22: Industry Landscape
Industry Landscape ▪ Market Opportunity ▪ Factors Driving Industry Growth 03 21
Slide 23: Markets Opportunity
Markets Opportunity Pharmaceutical & Preclinical Food Testing Clinical Testing Environment Testing Electronics Testing Biopharmaceuticals 957.6 Global 405.5 127.3 124.7 76.6 40.5 76.2 19.5 11.1 20.2 6.8 13.4 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2028 2022 | 2030 2021 | 2031 (USD bn) CAGR: 11.3%
Slide 24: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Discovery Electrical & Food Environment & Development Electronics Testing Testing Testing Increasing demand for Growing international Surge in demand for Increase in regulations new drug innovations, food regulations, certification services of to address the grow
Slide 25: Our Competitive Advantage
Our Competitive Advantage ▪ Our Position in the CRTO Landscape ▪ Our Strength 04 24
Slide 26: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape 1 Pharma Analytical & Preclinical 4 Food Testing #1 in India #1 in India Customers – 90% of India top 20 Customers – 70% of India top 10 36% revenues from overseas 2 Clinical Research 5 Environment Among the most reputed CROs in India Among top 5 in India 75% of re
Slide 27: Our Strengths
Our Strengths QUALITY CUSTOMER Long & successful CENTRICITY regulatory track record – Long term cGMP, GLP, GCP partnerships with customers INFRASTRUCTURE KNOWLEDGE Unparalleled lab Multi-disciplinary, infrastructure in the knowledgeable, skilled country. Gold LEED and trained manpower certified Viva
Slide 28: Way Forward
Way Forward ▪ Our Key Growth Drivers & Strategies 05 27
Slide 29: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational strategies Best practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate governance in markets ✓ Service innovations ✓ Hiring right talent ✓ Risk management ✓ Growing d
Slide 30: Thank You
Thank You November 2024 VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Vimta Labs Ltd. Plot Number 142, IDA Phase 2 Narahai Naidu Dodda, CFO Cherlapally, Hyderabad Narahai.Dodda@vimta.com Telangana, India. 500051 NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Siddesh Chawan Advait Bhadek